[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368652-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368652-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","impact-of-perioperative-dexmedetomidine-on-recurrence-and-survival-outcomes-in-oral-cavity-squamous-cell-carcinoma","Impact of perioperative dexmedetomidine on recurrence and survival outcomes in oral cavity squamous cell carcinoma","","Investigated whether perioperative dexmedetomidine (DEX) use affects oncological outcomes, including locoregional recurrence (LRR) and distant metastasis (DM), in patients undergoing curative surgery for oral cavity squamous cell carcinoma. A retrospective cohort study used Taiwan Cancer Registry data for stage I–IVB OCSCC treated between 2007 and 2019, applying 1:1 propensity score matching. After matching, multivariable Cox and competing risk analyses showed DEX independently associated with higher risks of LRR and DM, suggesting potential oncological risk and the need for prospective randomized validation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/impact-of-perioperative-dexmedetomidine-on-recurrence-and-survival-outcomes-in-oral-cavity-squamous-cell-carcinoma/368652/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/impact-of-perioperative-dexmedetomidine-on-recurrence-and-survival-outcomes-in-oral-cavity-squamous-cell-carcinoma/368652.png","ImageObject",300,407,{"name":42,"@type":43},"Đào","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about dexmedetomidine?","Question",{"text":63,"@type":64},"The study examines the association between perioperative dexmedetomidine (DEX) use and oncological outcomes, specifically locoregional recurrence and distant metastasis, in curatively treated oral cavity squamous cell carcinoma patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the study designed and who were the participants?",{"text":68,"@type":64},"This retrospective cohort study used Taiwan Cancer Registry Database patients with stage I–IVB OCSCC who underwent curative surgery from 2007 to 2019, with patients categorized by DEX exposure and matched 1:1 using propensity score matching.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings after propensity score matching?",{"text":72,"@type":64},"After matching, multivariable Cox regression showed perioperative DEX use was significantly associated with increased risks of locoregional recurrence (aHR 1.67) and distant metastasis (aHR 1.30), each with statistically significant p-values.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368652,1790243268,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118,"preview_page_count":33,"preview_urls":145},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Open access Original research  \nImpact of perioperative dexmedetomidineon recurrence and survival outcomes in oral cavity squamous cell carcinoma  \nMingyang Sun,1,2 Peilin Xie,1,3 Wan-Ming Chen,4,5,6 Szu-Yuan Wu  ,4,6,7,8,9 Jiaqiang Zhang1,2,3  \nTo cite: Sun M, Xie P, Chen WM, et al. Impact of perioperative dexmedetomidine on recurrence and survival outcomes in oral cavity squamous cell carcinoma. BMJ Health Care Inform 2025;32:e101344 . doi:10 . 1136/ bmjhci-2024-101344  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjhci-2024-101344](bmjhci-2024-101344)) .  \nMS and PX contributed equally. , S-YW and JZ contributed equally.  \nReceived 22 November 2024 Accepted 21 June 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Jiaqiang Zhang; [zhangjiq@zzu.edu.cn](zhangjiq@zzu.edu.cn)  \nDr Szu-Yuan Wu;  \n[szuyuanwu5399@gmail.com](szuyuanwu5399@gmail.com)  \nDr Mingyang Sun;  \n[mingyangsun1986@163.com](mingyangsun1986@163.com)  \nABSTRACT  \nObjectives To investigate the association between perioperative dexmedetomidine (DEX) use and oncological outcomes—including locoregional recurrence (LRR) and distant metastasis (DM)—in patients undergoing curative surgery for oral cavity squamous cell carcinoma (OCSCC) . Methods This retrospective cohort study used data from the Taiwan Cancer Registry Database and included patients with stage I–IVB OCSCC who underwent curative surgery between 2007 and 2019. Patients were categorised by DEX exposure status and matched 1:1 using propensity score matching (PSM) based on key clinical and demographic variables. Cox proportional hazards models and competing risk analyses were used to estimate the association between DEX use and oncological outcomes.  \nResults After PSM, 8024 patients (4012 per group) were included. Multivariable Cox regression showed that perioperative DEX use was significantly associated with increased risks of LRR (adjusted HR (aHR) 1.67; 95% CI 1.55 to 1.80; p\u003C0 .001) and DM (aHR 1 .30; 95% CI 1.19 to 1.42; p\u003C0 .001) .  \nDiscussion These findings suggest a potential oncological risk associated with perioperative DEX administration. Possible mechanisms include immune modulation and enhanced metastatic potential, as reported in preclinical studies. Further investigation is needed to clarify causal pathways and identify patient subgroups most affected. Conclusions Perioperative DEX use is independently associated with increased risks of LRR and DM in OCSCC patients. These results underscore the importance of cautious perioperative management and the need for prospective validation in randomised clinical trials.  \nINTRODUCTION  \nOral cavity squamous cell carcinoma (OCSCC) is the most prevalent form of head and neck cancer (HNC), ranking 16th globally.1 It is considered one of the most aggressive malignancies due to its high potential for metastasis and recurrence rate. 2–7 In Taiwan, the OCSCC subtype accounts for over 80% of HNC cases, whereas in Western countries, most HNCs are oropharyngeal cancers.2–7 This difference is largely due to the widespread practice of betel nut chewing  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ The role of dexmedetomidine in cancer recurrence has been suggested in preclinical models, but clinical data remain scarce.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ This is the first large-scale, propensity-matched analysis linking perioperative dexmedetomidine to higher risks of recurrence and metastasis in oral cavity squamous cell carcinoma.\u003Cbr>HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY |\n\n⇒ Anaesthesiologists and surgical teams should reevaluate perioperative dexmedetomidine use in high-risk cancer settings and consider alternative strategie","cbCaimQQgVZr1gG9","https://ap.wps.com/l/cbCaimQQgVZr1gG9","pdf",445031,"English","# Abstract\n## Objectives\n## Methods\n## Results\n## Discussion and Conclusions\n# Introduction\n## Background on OCSCC\n## Rationale for DEX investigation\n## Existing evidence and knowledge gap\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"What question does the study address about dexmedetomidine?\",\"answer\":\"The study examines the association between perioperative dexmedetomidine (DEX) use and oncological outcomes, specifically locoregional recurrence and distant metastasis, in curatively treated oral cavity squamous cell carcinoma patients.\"},{\"question\":\"How was the study designed and who were the participants?\",\"answer\":\"This retrospective cohort study used Taiwan Cancer Registry Database patients with stage I–IVB OCSCC who underwent curative surgery from 2007 to 2019, with patients categorized by DEX exposure and matched 1:1 using propensity score matching.\"},{\"question\":\"What were the key findings after propensity score matching?\",\"answer\":\"After matching, multivariable Cox regression showed perioperative DEX use was significantly associated with increased risks of locoregional recurrence (aHR 1.67) and distant metastasis (aHR 1.30), each with statistically significant p-values.\"}]","Impact of perioperative dexmedetomidine on recurrence and survival outcomes in oral cavity squamous cell carcinoma | PDF",1790177863,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44e1194fb6abed1ace2ec1c16ce14426.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db75e311d9987e601761943f316a3ecc.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15f908e43336ae8db5c429ec956343f8.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60eea553656ab3c5ef2c6cf63b216c70.webp",980,1306]